This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Tempus AI Class Action Lawsuit Filed
Business class action

Tempus AI Class Action Lawsuit Filed

Analysis based on 14 articles · First reported Jun 18, 2025 · Last updated Jul 02, 2025

Sentiment
-60
Attention
4
Articles
14
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against Tempus AI directly impacts its stock price and investor confidence, as evidenced by the over 19% drop in Tempus AI's stock after the RA Capital Management report. The allegations of inflated contracts, questionable joint ventures with SoftBank Group, and unethical billing practices by Ambry Genetics could lead to significant financial penalties and reputational damage for Tempus AI.

Biotechnology Legal Services Financial Services
Event Summary

Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Tempus AI and its executives for alleged violations of the Securities Exchange Act of 1934. The lawsuit covers purchasers of Tempus AI common stock between August 6, 2024, and May 27, 2025. Allegations include Tempus AI inflating contract values, engaging in a joint venture with SoftBank Group that appeared to 'round-trip' capital, and acquiring Ambry Genetics which had aggressive billing practices. Additionally, AstraZeneca is accused of reducing financial commitments to Tempus AI through a questionable 'pass-through payment' with Pathos AI. These issues were highlighted in a research report by RA Capital Management on May 28, 2025, which caused Tempus AI's stock to fall by over 19%. Investors have until August 12, 2025, to seek appointment as lead plaintiff.

Key Actions
100 Robbins Geller Rudman & Dowd LLP announced class action lawsuit Tempus AI
95 Tempus AI stock price fell
90 Tempus AI inflated contract values
90 RA Capital Management issued research report Tempus AI
80 Tempus AI engaged in joint venture SoftBank Group
70 Ambry Genetics used aggressive billing practices
70 AstraZeneca reduced financial commitments Tempus AI
Entities Involved
priv
Tempus AI
Tempus AI is the primary defendant in the class action lawsuit, accused of making false and misleading statements regarding its financial performance and business practices, which led to a significant drop in its stock price.
Importance 100.0 Sentiment -70.0
priv
Robbins Geller Rudman & Dowd LLP
Robbins Geller Rudman & Dowd LLP is the law firm announcing and leading the class action lawsuit against Tempus AI, representing investors who suffered losses.
Importance 80.0 Sentiment 50.0
priv
RA Capital Management
RA Capital Management issued a research report that highlighted numerous red flags regarding Tempus AI's management, operations, and financial reporting, leading to a significant stock price drop.
Importance 50.0 Sentiment 60.0
stock
SoftBank Group
SoftBank Group is mentioned in relation to a joint venture with Tempus AI, which is alleged to have involved 'round-tripping' capital to inflate Tempus AI's revenue, potentially impacting SoftBank Group's reputation.
Importance 40.0 Sentiment -20.0
priv
Ambry Genetics
Ambry Genetics, acquired by Tempus AI, is accused of having aggressive and potentially unethical billing practices, which contributes to the allegations against Tempus AI.
Importance 30.0 Sentiment -40.0
stock
AstraZeneca
AstraZeneca is implicated for allegedly reducing financial commitments to Tempus AI through a questionable 'pass-through payment' arrangement with Pathos AI, Inc., raising concerns about Tempus AI's revenue prospects.
Importance 30.0 Sentiment -10.0
priv
Pathos AI
Pathos AI is involved in a joint agreement with Tempus AI and AstraZeneca, through which AstraZeneca allegedly reduced its financial commitments to Tempus AI.
Importance 20.0 Sentiment -10.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.